ERBB2 and breast carcinoma: Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage ER-positive HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy, when there is a high risk of relapse (node-positive disease) [24].